| |
| MARCH 2009 |
|
Inject Some Thought
Vaccines are forecasted to be the fastest-growing sector in the pharmaceutical market. But if this market is to take off as predicted, will companies be able to stay on top of R&D, secure financial support and have the infrastructure to capitalise on it? Nic Paton talks to Rino Rappuoli, Novartis, and Jaap Goudsmit, Crucell. view pdf |
Crunch Time
Finances, not technologies are shaping the future of biopharma, writes Eric S Langer, BioPlan Associates. With data gleaned from BioPlan’s latest survey, he
reveals the latest trends in manufacturing budgets. view pdf |
Clear Indicators of Success
Failure during drug development is often due to lack of efficacy and/or unacceptable toxicity. New tools are required to enrich R&D programmes by improving the capacity to predict outcomes in humans. Stefano Persiani, Rottapharm-Madaus, discusses how the role of biomarkers in drug discovery and development can improve productivity. view pdf |
Hit the Target
The complexity, diversity and number of disease targets screened at high throughput screening (HTS) laboratories are increasing. William Downey, pharmaceutical business consultant, examines how much the targets are increasing and why directors must expand the capabilities of their HTS laboratories. view pdf |
Acid Test
Following his discovery that grapefruit juice can have a detrimental effect on the efficacy of certain medicines, David bailey, university of Western ontario, canada, has found that the problem extends to other juices. he talks to Nic Paton about his findings and what can be done to prevent patients from taking a potentially fatal dosage. view pdf
|
The Emerging Influence
Although the global pharmaceutical market experienced moderate growth in 2008, developed countries cannot take much of the credit as a worldwide recession and tighter regulations take their toll on mature markets. In contrast, sales in developing nations are witnessing a growth spurt. Murray Aitken, IMS Health, examines how far world markets are progressing and the reasons why. view pdf |
Power Shift
Economic downturn, patent expirations and a lack of new product pipelines are just some of the challenges facing pharma. Rüdiger Dorn, managing director, Worldwide Life Sciences, Microsoft Corporation, examines the knock-on effects for business and what
can be done to overcome the difficult times ahead. view pdf |
Kinks in the Chain
Cold chain management is closely monitored to control every link in the supply chain. But this is not always possible during times of crisis. Hugo Wegewijs, Johnson & Johnson, discusses the steps pharma can take to prepare for extraordinary circumstances.
view pdf |
|
Next Wave Model
Hailed as the ‘ultimate in lean manufacturing’, continuous processing is rapidly gaining momentum within the pharmaceutical industry. Professor Bernhardt Trout, Trout Research Group, discusses how continuous processing is
superior to batch processing and where the technology will go in the future.
view pdf |
Quality by Design
Efficiency gains to achieve world-class
manufacturing performance can no longer be realised through the quality-by-inspection method. Graham D Cook, Thirunellai G Venkateshwaran, and Stephen P Simmons, Wyeth Pharmaceuticals, discuss their company’s approach to increasing its understanding of development and manufacturing, which has resulted in high-quality pharmaceuticals. view pdf |
Managing Future Risk
In response to rising costs and falling reimbursement rates, many life sciences companies recognise the need to abandon high risks and high margins in favour of managed risks and variable margins. How effectively this change is made could mean life or death, writes John Rhodes, DTT Life Sciences Sector Leader. view pdf |
|
|
Difficult Opening
The aging population presents many challenges for pharma, not least the need to design packaging that makes products child resistant yet accessible to less dextrous elderly people. Keith Allen,
GlaxoSmithKline, explains to Jim Banks
how industry can balance these two vital criteria. view pdf |
French Pharma Connection
Over the last 20 years, France’s pharma industry has become one of the world’s success stories, but it is not immune to the pressures of an economic crisis. Despite its wealth of knowledge and expertise, Christian Lajoux, Leem, tells Jim Banks, collaboration between industry and state authorities will be crucial in supporting future growth.
view pdf |
The Dark Trade
The counterfeit drugs business continues to grow at an alarming rate. Andrew Jackson, Novartis, explains to
Jim Banks what measures are in place
and what needs to be done to secure
the future of legitimate pharmaceuticals.
view pdf |
